On November 4, Charles River Laboratories fell 5.07% in Pre-Market Trading to $335.5 per share, with turnover of $378.8 thousand.

The latest catalyst is the company’s newly released quarterly results, after which market trading around the gap between profit recovery and revenue softness intensified, reversing part of the prior session’s gains.

Into the report, consensus expectations had pointed to revenue of about $959 million, down 3.24% year over year, EBIT of about $217 million, up 16.64%, and adjusted EPS of about $2.97, up 27.13%. Recent analyst positioning had also turned more constructive, with target prices raised to $345 by JPMorgan, $340 by Morgan Stanley, and $357 by UBS. Despite that supportive backdrop, the post-results pullback suggests short-term funds remain focused on near-term expectation gaps rather than target-price momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)